Santen
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Santen sits in the top decile of US sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count).
Santen: 32 sponsored US clinical trials, none currently recruiting.
Santen sponsors 32 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 28 completed. 9 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Open-angle Glaucoma and Ocular Hypertension, with 1 trials.
Top-decile sponsor footprint
Santen ranks in the top decile of sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
28 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
32 total, page 1 of 1
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
NCT05665387
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
NCT05376176
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
NCT04742283
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
NCT03858894
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
NCT03711929
DE-117 Spectrum 5 Study
NCT03697811
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
NCT03691662
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
NCT03691649
A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
NCT03216902
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
NCT03211234
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
NCT02555306
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
NCT02401945
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
NCT02251938
Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
NCT02179008
A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration
NCT02022501
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
NCT01868126
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
NCT01654484
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
NCT01468168
Study Assessing Double-masked Uveitis Treatment
NCT01358266
Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT01279083
Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease
NCT01239069
Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
NCT01118754
A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
NCT00814944
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
NCT00868894
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
NCT00766337
Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery
NCT00764582
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
NCT00712491
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
NCT00656643
Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators
NCT00703313
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
NCT00650338
Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator
NCT00630019
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
NCT00401115
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 15 |
| Phase 3 | 6 |
| Phase 4 | 3 |
How the Santen early-phase archive is shaped
32 indexed studies, none listed as recruiting (0% open); 28 completed (88%).
Phase mix: 9 late (III/IV) vs 23 early (I/II) (early-phase heavy).
Top condition: Primary Open-angle Glaucoma and Ocular Hypertension (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Santen: archived-pipeline peers nationwide
Peers matched on 32 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Santen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 32 archived trials
- Aerie Pharmaceuticals · 32 trials · 0% recruiting
- Allina Health System · 32 trials · 3% recruiting
- Ardea Biosciences · 32 trials · 0% recruiting
- Hebrew SeniorLife · 32 trials · 19% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Santen page
32 registered trials is a research-attention snapshot, not an endorsement of Santen or any single study.
- None of Santen's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Primary Open-angle Glaucoma and Ocular Hypertension is the condition Santen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Open-angle Glaucoma and Ocular Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Santen pipeline card: 32 registered trials from official public datasets.Report a data error.